Monte Rosa Therapeutics, Inc. Common Stock vs. Halozyme Therapeutics, Inc.
GLUE
Monte Rosa Therapeutics, Inc. Common Stock
$12.13 -3.73%
VS HALOHalozyme Therapeutics, Inc.
$112.45 +2.53%
Halozyme Therapeutics, Inc. (HALO) comes out ahead, leading on 3 of 5 compared factors.
Size & Scale
| GLUE | HALO | |
|---|---|---|
| Market Cap | $1.03 billion | $12.76 billion |
| Revenue (TTM) | — | $1.66 billion |
| Net Income (TTM) | $-161,090,000 | $413.60 million |
HALO leads on 2 of 2 size & scale factors.
Valuation
| GLUE | HALO | |
|---|---|---|
| P/E Ratio | — | 32.78 |
| Price / Book | 2.12 | 88.91 |
| Price / Sales | — | 7.67 |
GLUE leads on 1 of 1 valuation factors.
Profitability
| GLUE | HALO | |
|---|---|---|
| Net Margin | — | 24.86% |
| Return on Equity | -33.06% | 288.13% |
HALO leads on 1 of 1 profitability factors.
Risk & Sentiment
| GLUE | HALO | |
|---|---|---|
| Short Interest | 0.86% | 9.79% |
GLUE leads on 1 of 1 risk & sentiment factors.
Dig deeper: GLUE overview, GLUE financials, HALO overview, HALO financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.